Prevalence of Amyloid Positron Emission Tomographic Positivity in Poststroke Mild Cognitive Impairment. Issue 10 (October 2016)

• Record Type: Journal Article
• Authors: Wollenweber, Frank Arne; Därr, Sonja; Müller, Claudia; Duering, Marco; Buerger, Katharina; Zietemann, Vera; Malik, Rainer; Brendel, Matthias; Ertl-Wagner, Birgit; Bartenstein, Peter; Rominger, Axel; Dichgans, Martin
• Is Part Of: Stroke. Volume 47:Issue 10(2016)
• Publication Date: 2016-10
• Subjects: amyloid -- magnetic resonance imaging -- mild cognitive impairment -- positron emission tomography -- stroke; Cerebrovascular disease -- Periodicals; Cerebral circulation -- Periodicals; 616.81
• DOI: 10.1161/STROKEAHA.116.013778
• Languages: English
• ISSNs: 0039-2499

Abstract

Abstract : Background and Purpose—: Mild cognitive impairment (MCI) is common after stroke and associated with poor outcome. However, the mechanisms underlying poststroke MCI (PS-MCI) are insufficiently understood. We performed amyloid-β positron emission tomography (PET) in a prospective cohort of stroke survivors to determine the role of amyloid pathology in PS-MCI. Methods—: We studied 178 consecutive patients enrolled into the prospective DEDEMAS study (Determinants of Dementia After Stroke). Follow-up visits 6 months post stroke included detailed cognitive testing, standardized magnetic resonance imaging, and amyloid-β imaging using flutemetamol ( 18 F) PET. MCI was defined by the modified Petersen criteria. Amyloid-positivity was assessed visually and quantitatively. Fifty-six (31%) patients agreed to undergo PET imaging. Results—: Thirty-eight (68%) patients who consented to PET imaging had PS-MCI. Visual assessment revealed amyloid PET positivity in 2 (5%) of the 38 PS-MCI patients and in 2 (11%) of the 18 cognitively healthy stroke survivors. There was no correlation between flutemetamol ( 18 F) standardized uptake value ratios and cognitive scores in the 56 patients. PS-MCI patients had significant cognitive impairments on executive function ( P <0.01) and memory tests ( P <0.01) when compared with cognitively healthy stroke survivors ( P <0.01). Conclusions—: The prevalence of amyloid-pathology in patients with PS-MCI is not increased when compared with cognitively healthy stroke survivors and to recent estimates for cognitively healthy elderly subjects. Factors other than amyloid-pathology likely contribute to the development of PS-MCI. Clinical Trial Registration—: URL:http://www.clinicaltrials.gov . Unique identifier: NCT01334749. Abstract : Supplemental Digital Content is available in the text.